VioQuest Pharmaceuticals to Present at Rodman & Renshaw 2nd Annual Global Healthcare Conference

MONMOUTH JCT., N.J.--May 3, 2005--Daniel Greenleaf, President and Chief Executive Officer of VioQuest Pharmaceuticals, Inc. (OTC BB: VQPH), will present at the Rodman & Renshaw 2nd Annual Global Healthcare Conference in Paris, France at 11:35 AM CEST on Wednesday, May 4, 2005. The forum of 150 presenting companies is being held at the Intercontinental Hotel.

About VioQuest Pharmaceuticals, Inc.

VioQuest Pharmaceuticals aims to acquire, develop and eventually bring to market late pre-clinical and early clinical stage therapies for oncological, metobalic and inflammatory diseases. VioQuest's subsidiary Chiral Quest, a pioneer in asymmetric chemocatalysis chirality, offers unique synthesis processes based upon its proprietary technology. This proprietary technology produces desired chiral compounds to increase the effectiveness and safety of the underlying drug. VioQuest provides its chiral products and services in all stages of product life cycles to well-known pharmaceutical and fine chemical companies worldwide.

Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements.